Prostatype Genomics AB (PROGEN) AI Stock Analysis

• Market Cap: kr48.89M
• Dividend Yield: N/A
• Average Volume (3M): 300.11K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.47
• Revenue Growth: -67.76%
• EPS Growth: 95.76%
• Country: SE
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.40
• Shares Outstanding: 59,189,320
• 10 Day Avg. Volume: 460,844
• 30 Day Avg. Volume: 300,114
• PEG Ratio: <0.01
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 17.06
• P/FCF Ratio: -0.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.2
• Revenue Forecast (FY): kr1.23M

• Rating: 42 Neutral
• Price Target: kr0.79 ▲(5.73% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is primarily held back by weak financial performance—small/declining revenue, persistent deep losses, and ongoing cash burn—with low leverage providing only partial offset. Technical indicators add modest downside pressure due to bearish momentum despite oversold readings. Valuation cannot be supported from earnings (negative P/E) and there is no dividend yield data.

Positive Factors

Low leverage / Balance sheet flexibility

Zero reported debt materially reduces financial risk and preserves optionality. With low leverage the company has greater capacity to raise equity or debt on reasonable terms and can prioritize investing in commercialization or R&D rather than servicing interest, improving runway while losses persist.

Negative Factors

Persistent negative cash flow

Consistent negative operating and free cash flow implies the business cannot self-fund growth and relies on external financing. Over months this erodes shareholder equity, increases funding risk, and constrains investment in sales/clinical validation crucial for diagnostic adoption and reimbursement.

Prostatype Genomics AB Business Overview & Revenue Model

Company Description

Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision med...

Read more

Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision med...

How the Company Makes Money

PROGEN’s revenue model is based on commercialization of its prostate-cancer prognostic test and related services. In practice, the company makes money primarily by generating test revenue (i.e., fees paid when the Prostatype test is ordered and pe...

Read more

PROGEN’s revenue model is based on commercialization of its prostate-cancer prognostic test and related services. In practice, the company makes money primarily by generating test revenue (i.e., fees paid when the Prostatype test is ordered and pe...

Prostatype Genomics AB Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	716.00K	594.00K	199.00K	1.36M	683.00K	10.00K
Gross Profit	-11.24M	-37.62M	1.92M	3.73M	683.00K	2.51M
EBITDA	-41.42M	-36.89M	-37.40M	-38.02M	-26.79M	-15.46M
Net Income	-45.31M	-44.50M	-41.05M	-41.44M	-29.09M	-15.63M
Balance Sheet
Total Assets	43.84M	50.86M	41.97M	49.22M	30.95M	40.20M
Cash, Cash Equivalents and Short-Term Investments	12.93M	9.07M	9.42M	2.68M	11.49M	20.33M
Total Debt	0.00	0.00	67.00K	11.67M	867.00K	1.27M
Total Liabilities	7.36M	24.33M	8.50M	24.55M	4.80M	4.30M
Stockholders Equity	36.48M	26.53M	33.47M	24.67M	26.15M	35.91M
Cash Flow
Free Cash Flow	-39.09M	-24.06M	-52.57M	-37.70M	-27.69M	-18.58M
Operating Cash Flow	-38.58M	-23.80M	-44.71M	-29.14M	-27.69M	-16.08M
Investing Cash Flow	-3.15M	-13.36M	-8.36M	-8.57M	0.00	-2.50M
Financing Cash Flow	52.87M	36.83M	59.75M	28.91M	18.85M	23.05M

Prostatype Genomics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.17, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 39.27 is Neutral, neither overbought nor oversold. The STOCH value of 44.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.

Prostatype Genomics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STABL	47 Neutral	kr12.81M	-1.92	-84.80%	―	―	64.02%
BIOVIC.B	45 Neutral	kr105.70M	-1.81	-72.82%	―	40.91%	57.92%
LARK	43 Neutral	kr42.77M	-1.97	―	8.47%	-94.12%	-25.83%
PROGEN	42 Neutral	kr48.89M	-0.23	-181.36%	―	-67.76%	95.76%